<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00259103</url>
  </required_header>
  <id_info>
    <org_study_id>RLX.CR.001</org_study_id>
    <nct_id>NCT00259103</nct_id>
  </id_info>
  <brief_title>Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor</brief_title>
  <official_title>A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety, Pharmacokinetics and Efficacy of Intravenous Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labour</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of rhRlx for cervical
      ripening, when compared to a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multicenter, randomized, double-blind, placebo-controlled, dose escalation study of healthy
      female subjects at ≥ 40 weeks gestation and who are scheduled for induction. A
      dose-escalation portion of the study is followed by a randomized, double-blind,
      placebo-controlled portion of the study. The endpoints include cervical ripening, as well as
      progression to labor and delivery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cervical ripening</measure>
    <time_frame>Through 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression to active labor and delivery</measure>
    <time_frame>Within 7 Days of Drug Infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Labor, Induced</condition>
  <arm_group>
    <arm_group_label>7.5 µg/kg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received intravenous (IV) infusion of 7.5 µg/kg/d serelaxin, all during part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 µg/kg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received intravenous (IV) infusion of 25 µg/kg/d serelaxin, all during part A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75 µg/kg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received IV infusion of 75 µg/kg/d serelaxin, some during part A and others during part B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who received IV infusion of placebo, some during part A and others during part B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serelaxin</intervention_name>
    <arm_group_label>7.5 µg/kg/d</arm_group_label>
    <arm_group_label>25 µg/kg/d</arm_group_label>
    <arm_group_label>75 µg/kg/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 40 years

          -  Normal pregnancy

          -  At least 40 weeks of gestation

          -  Otherwise healthy

        Exclusion Criteria:

          -  Anemia or hypertension

          -  Presence of chronic disease

          -  Endometriosis

          -  Known fetal anomaly

          -  Substance abuse

          -  History of cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Teichman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer of BAS Medical, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novosibirsk State Medical Academy</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evidence CPR</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>D.O. Ott Research Institute of Obstetrics and Gynecology</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2005</study_first_submitted>
  <study_first_submitted_qc>November 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2005</study_first_posted>
  <last_update_submitted>May 6, 2014</last_update_submitted>
  <last_update_submitted_qc>May 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relaxin</keyword>
  <keyword>pregnancy</keyword>
  <keyword>cervical ripening</keyword>
  <keyword>normal pregnancy at least at 40 weeks of gestation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methocarbamol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

